IPP Bureau
Fischer Medical Ventures and The Therapy Platform partner for mental healthcare
By IPP Bureau - June 15, 2024
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
By IPP Bureau - June 15, 2024
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Sun Pharma and Moebius Medical present Phase 2b study on MM-II
By IPP Bureau - June 15, 2024
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Jubilant Pharmova announces voluntary prepayment of US$ 75 million term loan
By IPP Bureau - June 15, 2024
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine
By IPP Bureau - June 14, 2024
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
By IPP Bureau - June 14, 2024
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
By IPP Bureau - June 14, 2024
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
AxoSim appoints Alif Saleh as CEO
By IPP Bureau - June 14, 2024
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Suven to acquire a majority stake in CDMO player ‘Sapala Organics’
By IPP Bureau - June 14, 2024
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Zydus receives USFDA’s tentative approval for Azilsartan Medoxomil and Chlorthalidone Tablets
By IPP Bureau - June 14, 2024
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
Torrent Pharmaceuticals gets Form 483 with 5 observations for Indrad facility
By IPP Bureau - June 13, 2024
There was no observation related to data integrity reported
Pfizer updates on Phase 3 study of investigational gene therapy for ambulatory boys with Duchenne Muscular Dystrophy
By IPP Bureau - June 13, 2024
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Kardium announces US$ 104 million in new financing for innovative Atrial Fibrillation Treatment
By IPP Bureau - June 13, 2024
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Lilly's tirzepatide was superior to placebo for MASH resolution
By IPP Bureau - June 13, 2024
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
